How payers and providers can manage GLP-1 therapy costs while improving clinical value

Download the white paper

LinkedIn
This field is for validation purposes and should be left unchanged.
Your Affiliation*
First Name*
First Last
Title*
Company*
Job Level*
State*
Email*
Business Phone*
Consent
- I consent to receiving updates on MedeAnalytics products, events and other information. You can unsubscribe at any time by clicking the unsubscribe link in any email. For more information, please see our Privacy Policy.

GLP-1s are reshaping healthcare, but at a steep cost.

Spending on GLP-1s has surged more than 500% in just five years, creating unprecedented financial and operational pressure for healthcare organizations. While GLP-1 therapies offer meaningful benefits for patients facing weight, diabetes, and cardiovascular challenges, long-term sustainability for payers and providers is threatened by uncontrolled growth, inconsistent adherence, and limited visibility into outcomes.

How can organizations unlock the clinical promise of GLP-1s without sacrificing financial performance?

This white paper examines why traditional utilization management approaches are not enough to control this growth and outlines how a data-driven framework can help manage GLP-1 use at scale.

Learn how integrated analytics can improve patient targeting, forecast demand, align costs with outcomes, and support value-based care goals, transforming GLP-1 management from a reactive cost challenge into a strategic advantage.